[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644897":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":7,"responsibleParty":24,"collaborators":7,"id":26,"slug":7,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":7,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":34,"phases":7,"briefSummary":35,"conditions":36,"keywords":40,"overallStatus":42,"whyStopped":7,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":47,"locationsCount":7},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Vepugratinib","Administered orally",[14],"LY3866288",[16],{"name":17,"affiliation":5,"role":18},"Contact Lilly at 1-800-LillyRx (1-800-545-5979)","STUDY_DIRECTOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":7},"The Lilly Answers Center","CONTACT","1-800-LillyRx (1-800-545-5979)",{"type":25,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100644897",false,"NCT07675057","Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors","Expanded Access for Vepugratinib in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors","Inclusion Criteria:\n\n* Have metastatic urothelial carcinoma (UC) or other solid tumor with a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration.\n* Have exhausted other approved treatments, including erdafitinib for UC.\n* Are not eligible for an ongoing vepugratinib clinical trial\n\nExclusion Criteria:\n\n* Currently enrolled in an ongoing clinical study of vepugratinib\n* Have a known severe (greater than or equal to (≥) Grade 3) hypersensitivity to any component or excipient of vepugratinib.\n* Current evidence of corneal keratopathy or retinal disorder confirmed by ocular examination. Exception: Individuals with asymptomatic ophthalmic conditions assessed by the investigator to pose minimal risk.\n* Significant cardiovascular disease:\n* Are pregnant, breastfeeding, or intent to become pregnant during the study or within 6 months of the last dose of study intervention.","ALL","18 Years","EXPANDED_ACCESS","The treating physician\u002Finvestigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.",[37,38,39],"Urinary Bladder Neoplasms","Neoplasm Metastasis","Carcinoma, Transitional Cell",[41],"Metastatic Urothelial Carcinoma","AVAILABLE","2026-06-23",{"date":45,"type":46},"2026-06-30","ACTUAL",{"name":5,"class":6}]